RPG Life Sciences API acquisitions have quickly changed the scale of the drugmaker’s active pharmaceutical ingredient business. In five weeks, the company committed ₹215 crore to acquire Actis Generics and the API and intermediates business of Raghava Life Sciences. It now has more than ₹500 crore available for further deals, according to Managing Director Ashok Nair, and is evaluating assets that can add differentiated chemistry, regulatory access, customers and export capability.
The immediate transactions are straightforward. RPG Active Pharma, a wholly owned subsidiary of RPG Life Sciences, agreed last week to acquire Raghava Life Sciences’ API and intermediates business for up to ₹135 crore. That followed the ₹80-crore acquisition of Actis Generics on July 29. RPG has described the transactions as part of a “buy-and-build” strategy aimed at creating a larger, integrated API platform.
The more significant development is the change in operating scale. According to Nair, RPG Active Pharma’s manufacturing capacity has risen from 110 kilolitres to 505 kilolitres. Its product portfolio has expanded from 14 products to 45, while its customer base has grown from 123 to more than 250. Employee strength has increased from 217 to over 500, and the research and development pipeline has expanded from 12 products to 28.
These numbers show that the acquisitions are intended to add more than physical plant. The strategy combines manufacturing capacity with product portfolios, technical capabilities, regulatory approvals and customer relationships. For an API business, that combination can determine whether installed capacity becomes commercial revenue or remains underutilised infrastructure.
Raghava’s facility near Hyderabad adds about 300 kilolitres of installed capacity to the RPG platform. The plant has EU-GMP and WHO-GMP approvals, while the business has regulatory credentials that include a Certificate of Suitability to the European Pharmacopoeia, EU Written Confirmation and Korea Drug Master File approvals. These approvals provide access to regulated or export-oriented markets, although the supplied information does not establish the scale of revenue currently generated from each market.
The Hyderabad facility is also central to the utilisation question. Actis and Raghava together generated about ₹70 crore in FY26 revenue, but Raghava’s plant is substantially underutilised. Nair said the existing infrastructure could support about ₹200 crore in annual revenue at fuller utilisation without significant incremental capital expenditure. That estimate makes utilisation, rather than only acquisition volume, the next test of the strategy.
The distinction matters because buying capacity does not automatically create demand. RPG plans to raise utilisation through new customers, geographic expansion and integration with Actis and its existing API operations. The company’s ability to convert those assets into revenue will depend on product demand, customer qualification, regulatory permissions, manufacturing execution and the economics of each product. The source material provides the company’s capacity and revenue assessment but does not provide a post-acquisition utilisation rate or a detailed product-level profitability breakdown.
RPG’s approach also reflects a broader change in how pharmaceutical companies assess supply chains. The company is positioning the acquisitions against efforts by global drugmakers to diversify pharmaceutical sourcing and reduce excessive dependence on China. In that setting, an API manufacturer’s value may lie not only in its production volume but also in the complexity of its chemistry, the markets it can legally serve and the customer relationships already attached to its products.
That does not mean every asset with regulatory approval is strategically attractive. Nair said US Food and Drug Administration-approved manufacturing capability forms part of RPG’s longer-term strategy, but the company would not acquire a facility merely for the approval. He identified chemistry, product basket, customers, utilisation potential and economics as the conditions that would need to be compelling. This provides an important qualification to the acquisition plan: regulatory access is an input into the strategy, not a substitute for commercial viability.
The company’s stated export ambition is also broader than the United States. The approvals associated with Raghava include European and Korean credentials, and RPG has said it wants to strengthen its presence in overseas markets. The available information does not specify the geographical mix targeted by the company or the proportion of current API revenue derived from exports. What it does show is that RPG is building a platform with multiple regulatory pathways rather than tying the strategy to a single market.
The structure of the business is another relevant consideration. RPG Active Pharma is being developed primarily as an independent merchant API and advanced-intermediates business, rather than as a captive supplier to RPG Life Sciences’ formulations operations. Third-party customers, exports and selected contract development and manufacturing organisation opportunities are expected to form the larger growth opportunity, according to Nair.
That choice broadens the addressable market but also increases execution requirements. A captive model could provide a more predictable internal customer, while a merchant model requires the business to compete for external contracts and maintain a diversified customer base. It must also manage product qualification, delivery commitments and regulatory compliance across customers and jurisdictions. The supplied material does not indicate how the company’s customer concentration will change after the acquisitions.
The financial position gives RPG room to continue pursuing the strategy. The company remains debt-free and has more than ₹500 crore available for potential acquisitions, manufacturing expansion, product development and regulatory access. However, the company has not set a predetermined number of acquisitions. Nair said the timing of further transactions would depend on strategic fit, valuation, integration readiness and returns.
That condition is significant because the first two transactions have already increased the organisational footprint. Capacity has expanded nearly fivefold, from 110 kilolitres to 505 kilolitres, while the product portfolio has more than tripled from 14 to 45. The workforce has more than doubled, and the customer base has also expanded substantially. The next phase therefore involves integrating a considerably larger operating system, not simply adding another asset to an unchanged platform.
Integration will determine whether the reported scale produces the intended benefits. RPG will need to connect the acquired product portfolios with its research and development pipeline, manufacturing network, sales channels and regulatory resources. It will also need to decide which products receive development and commercial priority. The company’s stated plan to use existing infrastructure for higher revenue suggests that capital efficiency is part of the rationale, but the source does not provide a timetable for reaching the ₹200-crore revenue potential cited for Raghava’s facility.
The acquisitions also raise a question about the relationship between capacity and industrial resilience. Expanding domestic API capability can support supply-chain diversification, but resilience depends on more than available kilolitres. It requires reliable inputs, commercially viable products, regulatory access, customer demand and the ability to sustain production at competitive economics. RPG’s strategy addresses several of these dimensions through acquisitions, but the available evidence does not yet establish how much of the expanded capacity is contracted, export-linked or operationally integrated.
For the wider pharmaceutical manufacturing landscape, RPG’s moves illustrate why smaller API assets can become acquisition targets even when they are not fully utilised. A buyer may be purchasing a combination of plant, approvals, products, employees, customers and technical know-how. The value of the transaction is therefore linked to what the buyer can do with the combined platform, rather than only to the acquired facility’s existing revenue.
The evidence currently confirms a rapid expansion in RPG Active Pharma’s stated capacity, products, customers and workforce, supported by two acquisitions worth up to ₹215 crore in aggregate. It also confirms that the company has substantial capital available and intends to remain active, subject to valuation, strategic fit, integration readiness and returns. What remains uncertain is the speed at which the enlarged platform will raise utilisation, the revenue contribution from exports and third-party customers, and the financial returns from the acquisitions.
Those indicators will determine whether RPG’s buy-and-build strategy becomes a durable API business or remains primarily a rapid expansion programme. The next developments to monitor are the integration of Actis and Raghava, additional acquisitions, utilisation of the Hyderabad plant, new customer additions, regulatory expansion and the conversion of the company’s stated capacity into reported revenue.
